Discovery of a novel selective water-soluble SMAD3 inhibitor as an antitumor agent.
Bioorg Med Chem Lett
; 30(17): 127396, 2020 09 01.
Article
en En
| MEDLINE
| ID: mdl-32738967
ABSTRACT
Targeting the SMAD3 protein is an attractive therapeutic strategy for treating cancer, as it avoids the potential toxicities due to targeting the TGF-ß signaling pathway upstream. Compound SIS3 was the first selective SMAD3 inhibitor developed that had acceptable activity, but its poor water solubility limited its development. Here, a series of SIS3 analogs was created to investigate the structure-activity relationship for inhibiting the activation of SMAD3. On the basis of this SAR, further optimization generated a water-soluble compound, 16d, which was capable of effectively blocking SMAD3 activation in vitro and had similar NK cell-mediated anticancer effects in vivo to its parent SIS3. This study not only provided a preferable lead compound, 16d, for further drug discovery or a potential tool to study SMAD3 biology, but also proved the effectiveness of our strategy for water-solubility driven optimization.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Agua
/
Proteína smad3
/
Antineoplásicos
Límite:
Animals
/
Humans
Idioma:
En
Año:
2020
Tipo del documento:
Article